AbbVie Inc. (ABBV) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
ABBV's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
ABBV Revenue Analysis (2013–2024)
As of March 2, 2026, AbbVie Inc. (ABBV) generated trailing twelve-month (TTM) revenue of $59.64 billion, reflecting solid growth of +9.1% year-over-year. The most recent quarter (Q3 2025) recorded $15.78 billion in revenue, up 2.3% sequentially.
Looking at the longer-term picture, ABBV's 5-year compound annual growth rate (CAGR) stands at +11.1%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $58.05 billion in 2022.
Revenue diversification analysis shows ABBV's business is primarily driven by SKYRIZI (22%), H U M I R A (17%), and RINVOQ (11%).
When compared to Healthcare sector peers including AMGN (+9.9% YoY), GILD (+2.4% YoY), and NVO (+2.3% YoY), ABBV has underperformed the peer group in terms of revenue growth. Compare ABBV vs AMGN →
Peer Comparison
Compare ABBV's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ABBVCurrent | $59.6B | +9.1% | +11.1% | 16.2% | |
| AMGN | $36.8B | +9.9% | +7.6% | 40.5% | |
| GILD | $28.8B | +2.4% | +5.1% | 5.8% | |
| NVO | $297.2B | +2.3% | +18.5% | 41.4% | |
| BIIB | $9.8B | +1.4% | -6.1% | 19.1% | |
| SCLX | $57M | -26.8% | - | -147.4% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $56.33B | +3.7% | $39.43B | 70.0% | $9.14B | 16.2% |
| 2023 | $54.32B | -6.4% | $33.90B | 62.4% | $12.76B | 23.5% |
| 2022 | $58.05B | +3.3% | $40.64B | 70.0% | $18.12B | 31.2% |
| 2021 | $56.20B | +22.7% | $38.75B | 69.0% | $17.92B | 31.9% |
| 2020 | $45.80B | +37.7% | $30.42B | 66.4% | $11.36B | 24.8% |
| 2019 | $33.27B | +1.6% | $25.83B | 77.6% | $12.98B | 39.0% |
| 2018 | $32.75B | +16.1% | $25.04B | 76.4% | $6.38B | 19.5% |
| 2017 | $28.22B | +10.1% | $21.18B | 75.0% | $9.54B | 33.8% |
| 2016 | $25.64B | +12.2% | $19.80B | 77.2% | $9.34B | 36.4% |
| 2015 | $22.86B | +14.5% | $18.36B | 80.3% | $7.54B | 33.0% |
See ABBV's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ABBV Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare ABBV vs AGIO
See how ABBV stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is ABBV's revenue growth accelerating or slowing?
ABBV maintains +9.1% revenue growth, in line with its 5-year CAGR of +11.1%. TTM revenue stands at $59.6B. Growth rate remains consistent with historical average.
What is ABBV's long-term revenue growth rate?
AbbVie Inc.'s 5-year revenue CAGR of +11.1% reflects the sustained expansion pattern. Current YoY growth of +9.1% is near this long-term average.
How is ABBV's revenue distributed by segment?
ABBV reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.